Bendamustine Plus Rituximab Appears Effective in Treating First-Line, Transplant-Eligible Mantle Cell Lymphoma

Development and Validation of a Novel TNM Staging N-Classification of Oral Cavity Squamous Cell Carcinoma

Utilizing Biomarkers to Optimize Treatment for Upper Gastrointestinal Cancers

Survival Benefit With Checkpoint Inhibitors Versus Chemotherapy is Modified by Brain Metastases in Patients With Recurrent Small-Cell Lung Cancer

Evaluating Strategies and Approaches to Prevent Graft-Versus-Host Disease

ChatGPT's Limited Ability to Recommend Guideline-Based Cancer Treatments

Response Assessment of Post-Treatment Head and Neck Cancers to Determine Further Management Using NI-RADS (Neck Imaging Reporting and Data System): A Subgroup Analysis of a Randomized Controlled Trial

IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, HER2-, BRCA1/2 Mutant Breast Cancer

Bendamustine Plus Rituximab Appears Effective in Treating First-Line, Transplant-Eligible Mantle Cell Lymphoma

header-info

Nov, 02, 2022

Among younger patients with transplant-eligible mantle cell lymphoma (MCL), first-line rituximab plus bendamustine followed by autologous stem cell transplantation (ASCT) appears to be an effective treatment option, according to a retrospective analysis published in Blood Advances.